Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd

₹ 178 -0.56%
29 Mar - close price
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Revenue Sources
The company is a clinical stage bio-pharmaceutical company and earns its revenues from license fee/ royalty on technology and R&D services.[1]

  • Market Cap 5,767 Cr.
  • Current Price 178
  • High / Low 309 / 160
  • Stock P/E
  • Book Value -4.30
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value 1.00

Pros

  • Company is expected to give good quarter

Cons

  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -0.87%
  • The company has delivered a poor sales growth of -5.39% over past five years.
  • Debtor days have increased from 58.5 to 73.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Miscellaneous Industry: Miscellaneous

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
20 23 185 18 22 28 22 28 62 25 28 32 131
73 121 125 100 85 78 76 83 73 92 107 94 115
Operating Profit -54 -98 61 -82 -63 -50 -54 -55 -11 -67 -78 -63 16
OPM % -274% -433% 33% -467% -289% -180% -245% -196% -18% -264% -275% -198% 12%
1 3 1 3 2 0 0 5 0 0 0 0 0
Interest 0 2 2 1 4 4 5 3 2 2 2 3 3
Depreciation 2 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax -56 -100 57 -83 -68 -57 -61 -55 -16 -71 -82 -68 10
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Net Profit -56 -100 57 -83 -68 -57 -61 -55 -16 -71 -82 -68 10
EPS in Rs -2.12 -3.80 2.16 -3.19 -2.58 -2.16 -2.34 -2.09 -0.60 -2.61 -3.03 -2.52 0.37
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
58 29 87 167 156 161 181 78 183 77 253 137 216
65 99 104 134 191 224 304 321 334 387 388 324 407
Operating Profit -7 -70 -17 34 -35 -63 -123 -243 -151 -310 -135 -187 -191
OPM % -11% -241% -19% 20% -23% -39% -68% -310% -83% -404% -53% -136% -88%
1 1 2 10 3 3 14 54 14 10 5 7 0
Interest 0 0 4 6 0 2 2 0 0 3 11 13 10
Depreciation 3 3 3 4 7 8 8 8 8 9 11 10 11
Profit before tax -8 -72 -22 34 -40 -70 -119 -197 -145 -312 -151 -203 -212
Tax % 0% 0% 0% 12% 0% 0% 0% 0% 0% 0% 0% 0%
Net Profit -8 -72 -22 30 -40 -70 -119 -197 -145 -312 -151 -203 -212
EPS in Rs -0.34 -2.93 -0.91 1.23 -1.60 -2.83 -4.82 -7.85 -5.55 -11.92 -5.77 -7.48 -7.79
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 17%
5 Years: -5%
3 Years: -9%
TTM: 54%
Compounded Profit Growth
10 Years: %
5 Years: -24%
3 Years: -15%
TTM: -12%
Stock Price CAGR
10 Years: 5%
5 Years: -14%
3 Years: 23%
1 Year: -41%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
21 21 24 24 24 24 25 25 26 26 26 27 27
Reserves -15 -87 85 116 76 8 133 160 270 -45 -194 -230 -146
7 68 81 5 4 56 3 2 2 67 236 79 193
66 84 20 39 39 75 111 122 101 224 162 404 218
Total Liabilities 78 86 209 184 143 163 273 309 398 273 230 280 292
63 64 66 64 67 70 69 52 58 104 91 92 121
CWIP 1 1 0 1 0 1 1 3 24 32 5 26 5
Investments 2 0 97 6 0 0 10 108 211 8 6 12 2
11 21 46 112 76 92 192 146 106 128 127 150 164
Total Assets 78 86 209 184 143 163 273 309 398 273 230 280 292

Cash Flows

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
2 -69 -95 37 -41 -44 -128 -183 -172 -211 -152 -208
-8 -2 -99 44 53 -13 -7 -105 -102 155 2 -29
4 72 194 -81 -1 51 194 224 274 55 159 229
Net Cash Flow -1 0 -0 -0 11 -7 60 -63 0 0 9 -8

Ratios

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 16 54 105 61 47 21 78 82 20 76 25 74
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Days Payable
Cash Conversion Cycle 16 54 105 61 47 21 78 82 20 76 25 74
Working Capital Days -372 -899 72 129 21 -42 -59 -232 -98 -557 -96 -97
ROCE % -59% -1,034% -20% 21% -32% -71% -94% -143% -62% -183% -242%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Jan 2023
68.46 68.46 68.46 68.46 68.46 68.10 68.10 69.09 69.09 69.09 68.23 65.68
2.81 2.91 3.06 2.69 2.61 2.54 2.51 2.38 2.40 2.38 3.48 3.54
0.30 0.01 0.01 0.02 0.02 0.56 0.55 0.76 0.76 0.76 0.76 0.64
28.43 28.62 28.46 28.83 28.91 28.81 28.84 27.77 27.75 27.77 27.53 30.14

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents